Neuroendocrine differentiation in usual‐type prostatic adenocarcinoma: Molecular characterization and clinical significance
| Autor: | Iryna Samarska, Jonathan I. Epstein, Tamara L. Lotan, Harsimar B. Kaur, Mohamed Alshalalfa, Edward M. Schaeffer, Sanjana Murali, Jiayun Lu, Benjamin L. Maughan, Emmanuel S. Antonarakis, Corinne E. Joshu, Juan Miguel Mosquera, Farzana A. Faisal, Kaushal Asrani |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Ubiquitin-Protein Ligases Urology Adenocarcinoma Neuroendocrine differentiation Article Metastasis Cohort Studies 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Neuroendocrine Cells medicine Carcinoma Humans Enzalutamide PTEN Carcinoma Small Cell Retrospective Studies biology business.industry PTEN Phosphohydrolase Prostatic Neoplasms Chromogranin A Cell Differentiation Middle Aged medicine.disease Immunohistochemistry Neuroendocrine Tumors Prostatic Neoplasms Castration-Resistant Retinoblastoma Binding Proteins 030104 developmental biology Oncology chemistry Receptors Androgen 030220 oncology & carcinogenesis biology.protein Cancer research Tumor Suppressor Protein p53 business Signal Transduction |
| Zdroj: | Prostate |
| ISSN: | 1097-0045 0270-4137 |
| DOI: | 10.1002/pros.24035 |
| Popis: | BACKGROUND Small cell neuroendocrine (NE) carcinomas of the prostate classically lose androgen receptor (AR) expression, may harbor loss of the RB1, TP53, and PTEN tumor suppressor genes, and are associated with a poor prognosis. However usual-type adenocarcinomas may also contain areas of NE differentiation, and in this context the molecular features and biological significance are less certain. METHODS We examined the molecular phenotype and oncologic outcomes of primary prostate adenocarcinomas with ≥5% NE differentiation (≥5% chromogranin A-positive NE cells in any given tumor spot on tissue microarray) using three independent study sets: a set of tumors with paneth cell-like NE differentiation (n = 26), a retrospective case-cohort of intermediate- and high-risk patients enriched for adverse outcomes (n = 267), and primary tumors from a retrospective series of men with eventual castration-resistant metastatic prostate cancer (CRPC) treated with abiraterone or enzalutamide (n = 55). RESULTS Benign NE cells expressed significantly lower quantified AR levels compared with paired benign luminal cells (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text